185.45 USD
+8.69 (+4.92%)
At close: Feb 4, 2026
185.5 USD
+0.05 (+0.03%)
After Hours: 2/4/2026, 7:06:01 PM
Overall BIIB gets a fundamental rating of 6 out of 10. We evaluated BIIB against 524 industry peers in the Biotechnology industry. BIIB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BIIB is valued quite cheap, but it does not seem to be growing. With these ratings, BIIB could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
- BIIB had positive earnings in the past year.
- BIIB had a positive operating cash flow in the past year.
- BIIB had positive earnings in each of the past 5 years.
- BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BIIB's Return On Assets of 5.51% is amongst the best of the industry. BIIB outperforms 92.18% of its industry peers.
- With an excellent Return On Equity value of 8.84%, BIIB belongs to the best of the industry, outperforming 92.37% of the companies in the same industry.
- BIIB has a better Return On Invested Capital (9.70%) than 94.66% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 18.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- BIIB's Profit Margin of 15.98% is amongst the best of the industry. BIIB outperforms 92.56% of its industry peers.
- BIIB's Profit Margin has declined in the last couple of years.
- The Operating Margin of BIIB (28.50%) is better than 96.76% of its industry peers.
- BIIB's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 75.24%, BIIB belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
- In the last couple of years the Gross Margin of BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
- BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, BIIB has more shares outstanding
- Compared to 5 years ago, BIIB has less shares outstanding
- The debt/assets ratio for BIIB has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.30 indicates that BIIB is not in any danger for bankruptcy at the moment.
- The Altman-Z score of BIIB (3.30) is better than 69.47% of its industry peers.
- BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as BIIB would need 2.78 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 2.78, BIIB belongs to the best of the industry, outperforming 92.94% of the companies in the same industry.
- A Debt/Equity ratio of 0.35 indicates that BIIB is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.35, BIIB is doing worse than 68.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.3 |
ROIC/WACC1.15
WACC8.42%
2.3 Liquidity
- BIIB has a Current Ratio of 2.72. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of BIIB (2.72) is worse than 68.32% of its industry peers.
- BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.04, BIIB is not doing good in the industry: 73.47% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 2.51% over the past year.
- BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
- The Revenue has been growing slightly by 4.77% in the past year.
- Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- The Earnings Per Share is expected to grow by 0.59% on average over the next years.
- The Revenue is expected to decrease by -0.63% on average over the next years.
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 11.08, the valuation of BIIB can be described as very reasonable.
- Compared to the rest of the industry, the Price/Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.90% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.25, BIIB is valued rather cheaply.
- With a Price/Forward Earnings ratio of 12.01, BIIB is valued correctly.
- 98.09% of the companies in the same industry are more expensive than BIIB, based on the Price/Forward Earnings ratio.
- BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.50.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.08 | ||
| Fwd PE | 12.01 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaper than 98.47% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BIIB is valued cheaply inside the industry as 98.28% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.02 | ||
| EV/EBITDA | 7.75 |
4.3 Compensation for Growth
- The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
5. Dividend
5.1 Amount
- No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
185.45
+8.69 (+4.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-06 2026-02-06/bmo
Inst Owners96.04%
Inst Owner Change-1.64%
Ins Owners0.15%
Ins Owner Change0.74%
Market Cap27.21B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target193.25 (4.21%)
Short Float %3.19%
Short Ratio2.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)5.38%
PT rev (3m)10.41%
EPS NQ rev (1m)2.53%
EPS NQ rev (3m)-52.97%
EPS NY rev (1m)0.19%
EPS NY rev (3m)-5.23%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)-2.6%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.08 | ||
| Fwd PE | 12.01 | ||
| P/S | 2.7 | ||
| P/FCF | 12.02 | ||
| P/OCF | 11.09 | ||
| P/B | 1.49 | ||
| P/tB | 11.41 | ||
| EV/EBITDA | 7.75 |
EPS(TTM)16.74
EY9.03%
EPS(NY)15.45
Fwd EY8.33%
FCF(TTM)15.42
FCFY8.32%
OCF(TTM)16.73
OCFY9.02%
SpS68.62
BVpS124.11
TBVpS16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.3 |
F-Score5
WACC8.42%
ROIC/WACC1.15
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status of BIOGEN INC (BIIB) stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
How financially healthy is BIOGEN INC?
The financial health rating of BIOGEN INC (BIIB) is 7 / 10.